Pimavanserin use in a movement disorders clinic: a single-center experience
- 21 July 2018
- journal article
- research article
- Published by Springer Nature in Neurological Sciences
- Vol. 39 (10) , 1767-1771
Abstract
Parkinson’s disease psychosis (PDP) is a disabling non-motor symptom of Parkinson’s disease (PD) that is challenging to treat. Dopamine receptor blockers (DRB) are used to treat PDP, though these may be associated with adverse effects, including worsening of Parkinsonism. Pimavanserin, a selective 5-HT2A receptor inverse agonist, was recently FDA-approved for treatment of PDP; however, there is limited information on its long-term use in PDP patients.Keywords
This publication has 11 references indexed in Scilit:
- Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers InitiativeJournal of Neurology, Neurosurgery & Psychiatry, 2017
- Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson DiseaseJAMA Neurology, 2016
- Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trialThe Lancet, 2014
- Pimavanserin tartrate, a 5-HT2A receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteersSleep Medicine, 2011
- A randomized controlled trial of quetiapine for psychosis in Parkinson’s diseaseNeuropsychiatric Disease and Treatment, 2009
- SCOPA‐sleep and PDSS: Two scales for assessment of sleep disorder in Parkinson's diseaseMovement Disorders, 2008
- Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow upJournal of Neurology, Neurosurgery & Psychiatry, 2004
- What's atypical about atypical antipsychotic drugs?Current Opinion in Pharmacology, 2004
- Excessive daytime sleepiness in Parkinson's disease as assessed by Epworth Sleepiness Scale (ESS)Sleep Medicine, 2003
- Longitudinal outcome of Parkinson’s disease patients with psychosisNeurology, 2003